Clinical trial · Interventional
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer
NCT03961373CI-TRIAL-00038779Neo-D2plusrecruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions of NAC and obtaining informed consent, they will be registered and randomized to receive surgical D2 vs. D2plus lymphadenectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gastrectomy with D2 lymphadenectomy | Procedure | — | UNRESOLVED |
| Gastrectomy with D2plus lymphadenectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard Group
- description
- Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy
- interventionNames
- Procedure: Gastrectomy with D2 lymphadenectomy
- type
- EXPERIMENTAL
- label
- Experimental Group
- description
- Neoadjuvant chemotherapy + surgical gastrectomy with D2plus lymphadenectomy
- interventionNames
- Procedure: Gastrectomy with D2plus lymphadenectomy
Primary outcomes (1)
- measure
- Overall survival analysis
- timeFrame
- This outcome measure will be estimated from the time of randomization to the date of death or last follow up visit, assessed approximately 5 years after the disease diagnosis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age equal or greater than 18 years * IIA-IIIC histologically proven primary gastric adenocarcinoma, before the treatment with NAC. Not including gastro-oesophageal junction/cardia carcinoma but only Siewert 3, without any previous treatment (surgery and / or chemotherapy) for this diagnosis * Lack in CT scan of following: 1. Mediastinal lymph nodes 2. Lung metastases 3. Peritoneal metastases 4. Liver metastases 5. Pleural effusion, ascites 6. Metastases to para-aortic lymph nodes No 16a2/b1 7. Metastases to lymph nodes located in the "posterior" area (8p, 12 b/p, 13) 8. Extra-regional lymph node metastases * ECOG performance status ≤ 2 * No prior radio- or chemotherapy conflicting with the treatment of gastric cancer * No oesophageal invasion, or invasion \<=3cm * Negative peritoneal washing cytology findings and no peritoneal metastases in staging laparoscopy * No gastric stump cancer * No signs of cervical and subclavear lymph nodes or distal metastases * Patient's consent form obtained, signed and dated before beginning specific protocol procedures * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial Exclusion Criteria: * Contraindications for any sort of appropriate chemotherapy according to local standards * Linitis plastica * Second uncontrolled malignant tumour (synchronous or metachronous (last 5 years) other than Cis or mucosal cancer * Neoplasms involving the esophago-gastric junction (Siewert types I and II) * Expected unresectability after neo-adjuvant treatment or progression in metastases * Emergency surgery due to bleeding or perforation * Uncontrolled infections * Other serious underlying medical conditions that could impair the ability of the patient to participate in the study * Pregnant or lactating women * Significant neurologic or psychiatric disorders * Severe cardiac illness (NYHA class IV) * Under treatment of systemic steroids * Participation in any other clinical trial that might interfere with the results of this trial * Lack of compliance * Inability to fill in questionnaires (insufficient command of language, dementia, lack of time)
References
Publications (0)
Data not yet available
No reference posted for this study.